Allogene Therapeutics, Inc. (NASDAQ:ALLO) has 166 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Pfizer Inc | 31 Mar, 2026 | 22,032,040 | 0 | 0.00% | $49,792,410.00 |
| Pfizer Inc | 31 Mar, 2026 | 22,032,040 | 0 | 0.00% | $30,183,895.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 19,091,095 | 1,415,066 | 8.01% | $46,582,273.00 |
| TPG GP A, LLC | 31 Mar, 2026 | 18,716,306 | 0 | 0.00% | $45,667,787.00 |
| TPG GP A, LLC | 31 Mar, 2026 | 18,716,306 | 0 | 0.00% | $25,641,339.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 17,676,029 | 161,355 | 0.92% | $24,216,160.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 12,111,420 | -1,860,137 | -13.31% | $16,592,646.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 9,251,609 | 230,839 | 2.56% | $12,674,704.00 |
| State Street Corp | 31 Mar, 2026 | 8,660,306 | 5,898,906 | 213.62% | $21,131,147.00 |
| PRIMECAP MANAGEMENT CO/CA/ | 31 Mar, 2026 | 8,379,840 | 240,000 | 2.95% | $20,446,810.00 |
| PRIMECAP MANAGEMENT CO/CA/ | 31 Mar, 2026 | 8,139,840 | 1,060,532 | 14.98% | $11,151,581.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 6,921,350 | 6,921,350 | 0.00% | $16,888,094.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 6,793,620 | -5,317,800 | -43.91% | $16,576,432.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 5,380,902 | 5,380,902 | 0.00% | $13,130.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 5,375,456 | 1,952,015 | 57.02% | $13,116,113.00 |
| Patient Square Capital LP | 31 Mar, 2026 | 4,963,756 | 1,982,360 | 66.49% | $6,800,346.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 4,578,916 | 3,375,208 | 280.40% | $6,273,114.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 4,124,178 | 191,268 | 4.86% | $10,065,365.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 3,932,910 | 99,025 | 2.58% | $5,388,905.00 |
| Frazier Life Sciences Management, L.P. | 31 Mar, 2026 | 3,868,750 | 0 | 0.00% | $5,300,188.00 |